Management of Oesophageal and Gastric Cancers

  • David PropperEmail author
  • Kathryn Hawkesford
Part of the Clinicians’ Guides to Radionuclide Hybrid Imaging book series (CGRHI)


Oesophageal cancer aetiologically, therapeutically and prognostically should be divided into two common histological types, rather than considered together, although many of the treatments overlap. Squamous cancers can affect the entire oesophagus, whereas adenocarcinomas are confined to the distal oesophagus and gastro-oesophageal junction. Most tumours present at stage T3 or greater and/or are node positive, and cure with multimodality therapy is only around 15 %.


Early Gastric Cancer Endoscopic Mucosal Resection Oesophageal Cancer Argon Plasma Coagulation Combine Modality Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Kwee RM. Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: a systematic review. Radiology. 2010;254(3):707–17.CrossRefPubMedGoogle Scholar
  2. 2.
    Prasad GA, Wu TT, Wigle DA, et al. Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett’s esophagus. Gastroenterology. 2009;137(3):815–23.CrossRefPubMedGoogle Scholar
  3. 3.
    Siewert JR, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol. 2007;17(1):38–44.CrossRefPubMedGoogle Scholar
  4. 4.
    Allum WH, Blazeby JM, Griffin SM, et al. Guidelines for the management of oesophageal and gastric cancer. Gut. 2011;60(11):1449–72.CrossRefPubMedGoogle Scholar
  5. 5.
    Allum WH, Stenning SP, Bancewicz J, et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27(30):5062–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–21.CrossRefPubMedGoogle Scholar
  7. 7.
    Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. Cochrane Database Syst Rev. 2013;5:CD008107.Google Scholar
  8. 8.
    Stahl A, Ott K, Weber WA, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging. 2003;30(2):288–95.CrossRefPubMedGoogle Scholar
  9. 9.
    Yoshioka T, Yamaguchi K, Kubota K, et al. Evaluation of 18F-FDG PET in patients with advanced, metastatic, or recurrent gastric cancer. J Nucl Med. 2003;44(5):690–9.PubMedGoogle Scholar
  10. 10.
    Smyth E, Schoder H, Strong VE, et al. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer. Cancer. 2012;118(22):5481–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Tada M, Tanaka Y, Matsuo N, et al. Mucosectomy for gastric cancer: current status in Japan. J Gastroenterol Hepatol. 2000;15(Suppl):D98–102.CrossRefPubMedGoogle Scholar
  12. 12.
    Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315–21.CrossRefPubMedGoogle Scholar
  13. 13.
    Wagner AD, Unverzagt S, Grothe W, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010;(3):CD004064.Google Scholar
  14. 14.
    Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Kang JH, Lee SI, do Lim H, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012;30(13):1513–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Park SH, Lee WK, Chung M, et al. Quality of life in patients with advanced gastric cancer treated with second-line chemotherapy. Cancer Chemother Pharmacol. 2006;57(3):289–94.CrossRefPubMedGoogle Scholar
  17. 17.
    Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16(2):273–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.CrossRefPubMedGoogle Scholar
  19. 19.
    Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Barts Cancer InstituteQueen Mary University of LondonLondonUK
  2. 2.Department of Medical OncologyBarts Health NHS TrustLondonUK

Personalised recommendations